Team

Leadership

Dave.png

David Happel
Chief Executive Officer

Mr. Happel joins Chrono Therapeutics from Horizon Pharma, PLC where he was Executive Vice President of Commercial Development and Strategy. During his tenure at Horizon, Mr. Happel was responsible for the commercialization of Horizon’s five marketed orphan disease products and the development of Horizon’s rare disease pipeline portfolio. Prior to Horizon Pharma, he was the Chief Commercial Officer of Raptor Pharmaceuticals where he had worldwide responsibility for the commercialization of Raptor’s two marketed orphan disease products and the development of Raptor’s pipeline portfolio. Previously, Mr. Happel also held senior management positions at Allergen Research Corporation, Dynavax Technologies, Dr. Reddy’s Laboratories, Chiron Corporation and Intermune. Mr. Happel received his B.A. in Chemistry from Indiana University and his M.B.A in Marketing from Indiana State University.

David Happel
Chief Executive Officer
Tony.png

Anthony Rimac
Chief Financial Officer

Mr. Rimac joins Chrono from Aldea Pharmaceuticals where he was Chief Financial Officer. Prior to Aldea Tony served as C.F.O. of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), a neurology focused company and Aerovance, Inc., a privately held biopharmaceutical company, spun off from Bayer Pharmaceuticals in 2004, focused on development and commercialization of clinical-stage products for respiratory and allergic diseases. Tony has over 25 years of broad operating and finance experience including 18 years in the life sciences industry ranging from biotech, specialty pharmaceuticals, drug delivery and medical devices and has raised in excess of $400M in equity and debt capital and partnership financing.

Tony received an MBA from Santa Clara University's Graduate School of Business Administration, and a B.A. in Business Economic – Accounting Emphasis from the University of California at Santa Barbara. Tony is also a licensed Certified Public Accountant in the State of California (inactive).

Anthony Rimac
Chief Financial Officer
Patti.png

Patricia Oto, R.Ph.
Senior Vice President of Regulatory Affairs and Quality Assurance

Patti Oto has over 25 years of executive leadership experience with regulatory and quality oversight. Prior to joining Chrono Therapeutics, Patti was at Incline Therapeutics (acquired by The Medicines Company) where she served as the Vice President of Global Regulatory and Quality, managing the regulatory and quality activities for the analgesia pipeline. Previous to Incline, Patti worked in roles of increasing responsibilities in quality and regulatory at Onyx Pharmaceuticals (Amgen), Corgentech (Anesiva), Coulter (Corixa, GlaxoSmithKline), Genentech (Roche), and Syntex. Patti has worked on global regulatory submissions in support of marketing authorizations for biologics, drugs and drug/device combination products in several therapeutic areas including cardiovascular, metabolics, oncology and pain management.

Patti is a registered pharmacist and received her B.S. in Pharmacy from the University of New Mexico.

Patricia Oto, R.Ph.
Senior Vice President of Regulatory Affairs and Quality Assurance
Bernie.png

Bernie Andreas
Vice President of Engineering

Mr. Andreas has nearly 30 years of experience innovating and leading the development of medical device designs, programs and organizations. He most recently served as Director of R&D at Calibra Medical and Acclarent, both Johnson and Johnson companies, and has previously held various engineering positions at Xtent, The Foundry, Perclose, Innerdyne, and Devices for Vascular Intervention.

Mr. Andreas received Bachelors of Science degrees from the University of California at Davis in Mechanical Engineering and Material Science & Engineering. He is an inventor on over 100 US patents.

Bernie Andreas
Vice President of Engineering
 

Board of Directors

David Happel
Chief Executive Officer, Chrono Therapeutics

Wende Hutton
General Partner, Canaan Partners 

Steve James
Chairman and Former Chief Executive Officer, Labrys Biologics, Inc. and KAI Pharmaceuticals, Inc. 

Tim Kilgallon
Chief Executive Officer, Mazlo and Former Chief Executive Officer, Free & Clear, Inc.

Aidan King
Co-founder and Managing Partner, Fountain Healthcare

Alan Levy
Former Chief Executive Officer, Chrono Therapeutics

Liz Rockett
Director, Kaiser Permanente Ventures

James W. Young
Venture Partner, 5AM Ventures

 

 

Scientific Advisory Board

Neal Benowitz, M.D.
UCSF School of Medicine

Jonathan Bricker, Ph.D.
Faculty Member at the University of Washington and the Fred Hutchinson Cancer Research Center

Karl Fagerström, Ph.D.
Fagerström Consulting AB

Gary E. Swan, Ph.D.
Consulting Professor Stanford Prevention Research Center at Stanford University School of Medicine

 

 

Partners and Investors

5amVentures.png
AsahiKasei.png
CannanPartners.png
CotaCapital.png
EndeavourVision.png
FountainHealthcarePartners.png
HikmaVentures_2.png
MayoClinic.png
MissionBayCapital.png
NIH.png
RockHealth.png
XerayaCapital.png